TYM-3-98 is a selective inhibitor of PI3Kδ with an IC50 of 7.1 nM. It blocks the PI3Kδ/AKT signaling pathway, induces apoptosis in B-cell lymphomas, and effectively suppresses xenograft tumor growth in vivo.

Aprocitentan (ACT-132577) is a pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual antagonist of ETA/ETB with IC50 values of 3.4 nM and 987 nM, and pA2 values of 6.7 and 5.5, respectively.

Aprocitentan (ACT-132577) is a pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual antagonist of ETA/ETB with IC50 values of 3.4 nM and 987 nM, and pA2 values of 6.7 and 5.5, respectively.

TYM-3-98 is a selective inhibitor of PI3Kδ with an IC50 of 7.1 nM. It blocks the PI3Kδ/AKT signaling pathway, induces apoptosis in B-cell lymphomas, and effectively suppresses xenograft tumor growth in vivo.

TYM-3-98 is a selective inhibitor of PI3Kδ with an IC50 of 7.1 nM. It blocks the PI3Kδ/AKT signaling pathway, induces apoptosis in B-cell lymphomas, and effectively suppresses xenograft tumor growth in vivo.

YJ1206 is an orally bioavailable, highly specific and potent degrader of CDK12/13 with an IC50 of 12.55 nM in VCaP cells. It increases DNA damage, induces apoptosis, and demonstrates robust anti-tumor activity in vivo.

YJ1206 is an orally bioavailable, highly specific and potent degrader of CDK12/13 with an IC50 of 12.55 nM in VCaP cells. It increases DNA damage, induces apoptosis, and demonstrates robust anti-tumor activity in vivo.

YJ1206 is an orally bioavailable, highly specific and potent degrader of CDK12/13 with an IC50 of 12.55 nM in VCaP cells. It increases DNA damage, induces apoptosis, and demonstrates robust anti-tumor activity in vivo.

YJ1206 is an orally bioavailable, highly specific and potent degrader of CDK12/13 with an IC50 of 12.55 nM in VCaP cells. It increases DNA damage, induces apoptosis, and demonstrates robust anti-tumor activity in vivo.

MS41 is a highly potent and selective PROTAC degrader of eleven-nineteen leukemia (ENL) that recruits the von Hippel–Lindau (VHL) E3 ubiquitin ligase, with DC50 values of 3.50 nM (MV4;11), 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1). It suppresses oncogenic gene expression, inhibits leukemia cell proliferation, and reduces MLL-r leukemia progression in a […]